Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927909 | 0.72 | — | — | |
| SCHEMBL2204826 | 0.72 | ALDH1A1 (0.43) | ALDH1A1TSHRCYP2C9MEN1KMT2A | |
| SCHEMBL2115865 | 0.72 | ALDH1A1 (0.61) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL10872877 | 0.72 | — | — | |
| SCHEMBL1754710 | 0.72 | ALDH1A1 (0.61) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL5338908 | 0.70 | — | — | |
| SCHEMBL1370917 | 0.70 | — | — | |
| SCHEMBL14369117 | 0.69 | — | — | |
| SCHEMBL1372367 | 0.68 | SOAT1 (0.42) | ALDH1A1TSHRCYP2C9MEN1KMT2A | |
| SCHEMBL18512590 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559577-B2 | Chemical functionalization of cellulosic materials with diazo compounds | Centre National de la Recherche Scientifique—CNRS- (FR) | 2026-02-24 | — | — | US | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4622712-A1 | SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2 | Vertex Pharmaceuticals Incorporated (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-115916844-B | Chemically functionalizing cellulose materials with diazo compounds | 国家科学研究中心 | 2024-12-10 | — | — | CN | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024112899-A1 | SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | disclosed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2016086015-A1 | MYOGLOBIN-BASED CATALYSTS FOR CARBENE TRANSFER REACTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20130030170-A1 | ENANTIOSELECTIVE CYCLOPROPENATION OF ALKYNES | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | NATIONAL SCIENCE FOUNDATION | 2012-02-23 | — | — | US | disclosed |
| US-7144866-B2 | Avermectin derivatives | THE KITASATO INSTITUTE (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20040018993-A1 | Avermectin derivatives | KITASATO INSTITUTE,THE (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ALDH1A1 527/4885TSHR 2756/4885CYP2C9 1538/4885 |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | ALDH1A1 527/4885TSHR 2756/4885CYP2C9 1538/4885 |
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | PPOX, POR, PCCA | ALDH1A1 454/4885TSHR 4532/4885CYP2C9 998/4885 |
| US-20040018993-A1 | Avermectin derivatives | SUV39H2, SUV39H1, TET1 | ALDH1A1 2015/4885TSHR 960/4885CYP2C9 562/4885 |
| US-20130030170-A1 | ENANTIOSELECTIVE CYCLOPROPENATION OF ALKYNES | CYCS, CBR3, HCCS | ALDH1A1 1689/4885TSHR 4072/4885CYP2C9 635/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | ALDH1A1 527/4885TSHR 2756/4885CYP2C9 1538/4885 |
| US-12559577-B2 | Chemical functionalization of cellulosic materials with diazo compounds | ILK, MGAM, LPO | ALDH1A1 663/4885TSHR 3397/4885CYP2C9 1417/4885 |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | ALDH1A1 527/4885TSHR 2756/4885CYP2C9 1538/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | ALDH1A1 184/4885TSHR 2776/4885CYP2C9 349/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | ALDH1A1 100/4885TSHR 3830/4885CYP2C9 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.